Kimberly J. Popovits Sells 10,000 Shares of Genomic Health, Inc. (GHDX) Stock

Genomic Health, Inc. (NASDAQ:GHDX) insider Kimberly J. Popovits sold 10,000 shares of Genomic Health stock in a transaction on Thursday, June 14th. The shares were sold at an average price of $48.89, for a total value of $488,900.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Kimberly J. Popovits also recently made the following trade(s):

Get Genomic Health alerts: On Monday, May 14th, Kimberly J. Popovits sold 10,000 shares of Genomic Health stock. The shares were sold at an average price of $38.09, for a total value of $380,900.00. On Monday, April 16th, Kimberly J. Popovits sold 15,000 shares of Genomic Health stock. The shares were sold at an average price of $33.19, for a total value of $497,850.00.

GHDX stock traded up $0.16 during mid-day trading on Monday, hitting $49.75. 265,138 shares of the stock were exchanged, compared to its average volume of 209,295. Genomic Health, Inc. has a 12 month low of $26.54 and a 12 month high of $53.65. The firm has a market cap of $1.75 billion, a P/E ratio of 4,975.00 and a beta of 0.64.

Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings results on Wednesday, May 2nd. The medical research company reported $0.13 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.05 by $0.08. Genomic Health had a positive return on equity of 3.15% and a negative net margin of 1.95%. The firm had revenue of $92.60 million during the quarter, compared to analyst estimates of $88.95 million. During the same quarter in the previous year, the company posted ($0.02) earnings per share. The company’s revenue was up 12.5% compared to the same quarter last year. equities analysts expect that Genomic Health, Inc. will post 0.47 earnings per share for the current fiscal year.

Several equities research analysts recently issued reports on the company. ValuEngine raised Genomic Health from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 7th. LADENBURG THALM/SH SH lowered Genomic Health from a “buy” rating to a “neutral” rating and set a $33.00 price target for the company. in a research note on Wednesday, June 13th. Canaccord Genuity lifted their price target on Genomic Health from $41.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, June 4th. BidaskClub raised Genomic Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 12th. Finally, Zacks Investment Research raised Genomic Health from a “hold” rating to a “strong-buy” rating and set a $42.00 price target for the company in a research note on Wednesday, May 9th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the stock. Genomic Health currently has a consensus rating of “Hold” and an average target price of $34.22.

A number of hedge funds have recently modified their holdings of GHDX. Teacher Retirement System of Texas purchased a new position in shares of Genomic Health in the fourth quarter worth about $242,000. Virtu Financial LLC purchased a new position in shares of Genomic Health in the fourth quarter worth about $261,000. Guggenheim Capital LLC purchased a new position in shares of Genomic Health in the first quarter worth about $264,000. MetLife Investment Advisors LLC purchased a new position in shares of Genomic Health in the fourth quarter worth about $301,000. Finally, Legal & General Group Plc increased its holdings in shares of Genomic Health by 67.8% in the first quarter. Legal & General Group Plc now owns 12,300 shares of the medical research company’s stock worth $385,000 after buying an additional 4,968 shares during the period. 89.77% of the stock is owned by hedge funds and other institutional investors.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Hot Medical Stocks To Invest In Right Now

tags:RESI,PINC,UDR,NVR,

Equities research analysts at Guggenheim assumed coverage on shares of Inspire Medical Systems (NASDAQ:INSP) in a research note issued on Tuesday. The firm set a “buy” rating and a $40.00 price target on the stock. Guggenheim’s price objective suggests a potential upside of 30.68% from the stock’s current price.

INSP has been the topic of several other reports. Goldman Sachs Group initiated coverage on shares of Inspire Medical Systems in a research report on Tuesday. They issued a “neutral” rating and a $25.00 target price on the stock. Stifel Nicolaus initiated coverage on shares of Inspire Medical Systems in a research report on Tuesday. They issued a “buy” rating and a $42.00 target price on the stock.

Hot Medical Stocks To Invest In Right Now: Altisource Residential Corporation(RESI)

Advisors' Opinion:

• [By Logan Wallace]

  Front Yard Residential (NYSE:RESI) issued its quarterly earnings data on Tuesday. The real estate investment trust reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.02), Morningstar.com reports. Front Yard Residential had a negative return on equity of 25.77% and a negative net margin of 196.93%.

Hot Medical Stocks To Invest In Right Now: Premier, Inc.(PINC)

Advisors' Opinion:

• [By Stephan Byrd]

  Get a free copy of the Zacks research report on Premier (PINC)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Lisa Levin]

   

  Companies Reporting After The Bell Hertz Global Holdings, Inc. (NYSE: HTZ) is projected to post quarterly loss at $1.31 per share on revenue of $1.97 billion. International Flavors & Fragrances Inc. (NYSE: IFF) is estimated to post quarterly earnings at $1.59 per share on revenue of $909.36 million. Zillow Group, Inc. (NASDAQ: ZG) is expected to post quarterly earnings at $0.06 per share on revenue of $294.79 million. General Cable Corporation (NYSE: BGC) is estimated to post quarterly earnings at $0.15 per share on revenue of $980.61 million. Central Garden & Pet Company (NASDAQ: CENT) is expected to post quarterly earnings at $0.84 per share on revenue of $598.45 million. Cabot Corporation (NYSE: CBT) is estimated to post quarterly earnings at $1 per share on revenue of $746.42 million. Fabrinet (NYSE: FN) is expected to post quarterly earnings at $0.71 per share on revenue of $319.71 million. National General Holdings Corp. (NASDAQ: NGHC) is projected to post quarterly earnings at $0.55 per share on revenue of $1.08 billion. The Navigators Group, Inc. (NASDAQ: NAVG) is estimated to post quarterly earnings at $0.75 per share on revenue of $320.92 million. Diplomat Pharmacy, Inc. (NYSE: DPLO) is expected to post quarterly earnings at $0.22 per share on revenue of $1.29 billion. Trex Company, Inc. (NYSE: TREX) is projected to post quarterly earnings at $1.19 per share on revenue of $172.22 million. AMC Entertainment Holdings, Inc. (NYSE: AMC) is expected to post quarterly earnings at $0.09 per share on revenue of $1.35 billion. Envision Healthcare Corporation (NYSE: EVHC) is projected to post quarterly earnings at $0.64 per share on revenue of $2.02 billion. Regal Beloit Corporation (NYSE: RBC) is estimated to post quarterly earnings at $1.23 per share on revenue of $869.64 million. Amedisys, Inc. (NASDAQ: AMED) is projected to post quarterly earnings at $0.67 per share on revenue of $39

Hot Medical Stocks To Invest In Right Now: United Dominion Realty Trust, Inc.(UDR)

Advisors' Opinion:

• [By Benzinga News Desk]

  Trump to grant lifeline to money-losing coal power plants: Link $

  ECONOMIC DATA Nonfarm Payrolls for May 223.0K vs 189.0K Est; Prior 164.0K. Private Payrolls for May 218.0K vs 183.0K Est; Prior 168.0K US Unemployment Rate for May 3.80% vs 3.90% Est; Prior 3.90% The manufacturing PMI for May is schedule for release at 9:45 a.m. ET. Data on construction spending for April will be released at 10:00 a.m. ET. The ISM manufacturing index for May is schedule for release at 10:00 a.m. ET. The Baker Hughes North American rig count report for the latest week will be released at 1:00 p.m. ET. ANALYST RATINGS Stifel Upgrades UDR (NYSE: UDR) from Hold to Buy Imperial Upgrades American Airlines (NASDAQ: AAL) from In-Line to Outperform Imperial Downgrades Southwest Airlines (NYSE: LUV) from Outperform to In-Line JPMorgan Downgrades Scotts Miracle-Gro (NYSE: SMG) from Neutral to Underweight

  This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here.

• [By Stephan Byrd]

  News articles about United Dominion Realty Trust (NYSE:UDR) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. United Dominion Realty Trust earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave news articles about the real estate investment trust an impact score of 47.5630416063411 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Hot Medical Stocks To Invest In Right Now: NVR Inc.(NVR)

Advisors' Opinion:

• [By Stephan Byrd]

  NVR, Inc. (NYSE:NVR) Director Susan Williamson Ross purchased 70 shares of the company’s stock in a transaction on Tuesday, May 15th. The stock was purchased at an average price of $2,995.20 per share, for a total transaction of $209,664.00. Following the purchase, the director now directly owns 64,191 shares of the company’s stock, valued at approximately $192,264,883.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

• [By Ethan Ryder]

  NVR (NYSE: NVR) and LGI Homes (NASDAQ:LGIH) are both construction companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

• [By Jason Hall]

  Priestley:�Yeah,�absolutely. The first stock that you mentioned was NVR (NYSE:NVR). They focus on building luxury homes in Delaware, Maryland, North Carolina, Pennsylvania,�and Virginia. They have three distinct brands:�Ryan Homes, NV Homes and Heartland Homes. They're�actually the most expensive, I think, of the stocks that we're going to talk about today. Their P/E is at 24X. But they're also the biggest, and the past 12 months have seen the stock come up almost 50%. So, great pick! What exactly attracted you to NVR?

• [By Tyler Crowe]

  For a business that is supposed to be relatively seasonal and cyclical, NVR (NYSE:NVR) has been enjoying an impressive run of growth. Not only did the company deliver impressive top- and bottom-line expansion, but it also showed positive trends on just about every operating metric. If there was one thing to critique, it's how management is dividing up the benefits of these boom times.�

Fiat Chrysler to Form U.S. Finance Arm; in Talks With Santander

Fiat Chrysler Automobiles NV plans to form its own financing business in the U.S. and has started discussions with partner Santander Consumer USA Holdings Inc., which it has an option to buy out.

That would allow Fiat Chrysler to “participate more fully in capturing value from emerging platforms,” Chief Financial Officer Richard Palmer said Friday in a presentation near Turin, Italy, confirming a Bloomberg report earlier in the week that the automaker was considering such a plan.

Buying out Dallas-based Santander Consumer could add $500 million to $800 million in incremental pretax earnings within four years, Palmer said. Fiat could also start its own business, in which case the automaker envisions about $100 million in incremental profit, he said.

Fiat Chrysler shares fell 4.1 percent to $22.27 at 10:07 a.m. in New York, while Santander Consumer gained 2.5 percent, after tumbling as much as 9.6 percent on Wednesday following the Bloomberg report.

Fiat Chrysler exiting its deal “would require some payment above book value” to Santander Consumer, Kevin Barker, a Piper Jaffray & Co. analyst, said in a note. Given the cost, a full buyout “is a low probability,” he said, adding “we would be buyers” of Santander based on the news.

Sergio Marchionne, the automaker’s chief executive officer, told investors Friday he’ll institute a dividend for the first time since Fiat and Chrysler merged in 2014. The firm said it aims to double profit over the next five years, generating about 30 billion euros ($35 billion) in industrial free cash flow in that span. Fiat Chrysler has no plans to spin off its Alfa Romeo and Maserati brands, Marchionne said.

Santander has struggled to reach market share targets that it set along with Fiat Chrysler as part of the 10-year financing agreement the two companies signed in 2013. The lender financed 28 percent of Fiat Chrysler’s total loans and leases as of the end of December, well short of a goal to reach 65 percent by the end of April, according to a regulatory filing.

Last August, Santander’s new CEO, Scott Powell, met with Fiat Chrysler executives during his first day on the job to find ways to capture more business.

“There are a number of possibilities for the next phase of our relationship,” Santander said in an emailed statement. “In the meantime, we remain focused on providing Chrysler dealers and customers with the same superior service they have come to expect.”

Santander Consumer will hold a conference call to discuss the matter at noon New York time, the company said in a separate statement.

Missed Targets

Chrysler Capital hasn't performed like a captive for Fiat Chrysler

Source: Santander regulatory filing

.chart-js { display: none; }

The lender’s financing agreement with Fiat Chrysler can be terminated if Chrysler Capital fails to meet origination goals within the first five years, according to Santander filings, which note that this could have a “materially adverse impact” on its business.

In forming its own captive lender, Fiat Chrysler could also pose problems for Ally Financial Inc. The bank originated $2.44 billion of loans and leases for Fiat Chrysler dealers last year, which was more than a quarter of its consumer automotive business, according to a regulatory filing.

Ally shares slipped 2 cents to $25.63 in New York. The Detroit-based company said in an emailed statement that it’s created a strong business as an independent competitor and will continue to support Fiat Chrysler dealers.

— With assistance by Jennifer Surane

LISTEN TO ARTICLE 3:20 Share Share on Facebook Post to Twitter Send as an Email Print